Skip to content

Clinical trials

Neuromuscular Diseases trials in France with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neuromuscular Diseases Phase: Not applicable Country / region: France Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20103
20111
20124
20132
20142
20155
20161
20182
20192
20211
20222
20233
20241
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Unknown status7
Recruiting4
Terminated2
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Centre d'Investigation Clinique et Technologique 80512
Institut de Myologie, France7
Assistance Publique - Hôpitaux de Paris3
Centre Hospitalier Universitaire de Nice2
Assistance Publique Hopitaux De Marseille1
Groupe Hospitalier du Havre1
University Hospital, Angers1
University Hospital, Clermont-Ferrand1
University Hospital, Grenoble1
University Hospital, Lille1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neuromuscular Diseases31
Respiratory Insufficiency5
Myotonia Congenita4
Amyotrophic Lateral Sclerosis3
Glycogen Storage Disease3
Mitochondrial Myopathies2
Muscular Atrophy, Spinal2
Muscular Diseases2
Muscular Dystrophies2
Muscular Dystrophy, Duchenne2

Trials

Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.